• Fabrizio D'Ascenzo, Claudio Moretti, Pierluigi Omedè, Enrico Cerrato, Erika Cavallero, Fikret Er, Davide Giacomo Presutti, Francesco Colombo, Gabriele Crimi, Federico Conrotto, James J Dinicolantonio, Shaoliang Chen, Abhiram Prasad, Giuseppe Biondi Zoccai, and Fiorenzo Gaita.
• Division of Cardiology, Department of Internal Medicine, Città Della Salute e Della Scienza, Turin, Italy.
• EuroIntervention. 2014 Jan 1;9(12):1463-71.

AimsTo establish the cardioprotective effect of remote ischaemic preconditioning (RIPC) in patients undergoing percutaneous coronary intervention (PCI).Methods And ResultsPubmed (MEDLINE), Cochrane and Embase were systematically searched for randomised controlled trials of RIPC in patients undergoing PCI. Periprocedural myocardial infarction (PMI) was the primary endpoint (defined as troponin elevation >3 times upper reference limit) and C-reactive protein (CRP) was a secondary endpoint. Five studies with 731 patients were included. The median age of the patients was 62 (59-68) years old, 25% were female (23-33), 29% (25-33) had diabetes mellitus, and 26.5% (19-31) presented with multivessel disease. RIPC significantly reduced the incidence of PMI (odds ratio: 0.58 [0.36, 0.93]; I2 43%), with a greater benefit when performed using the lower limb (0.21 [0.07-0.66]) compared to the upper limb (0.67 [0.46-0.99]). This reduction was enhanced for patients with multivessel disease (beta -0.05 [-0.09;-0.01], p=0.01) and with type C lesion (beta -0.014 [-0.04;-0.010], p=0.01) and did not vary according to age, female gender, diabetes mellitus, use of beta-blockers and of angiotensin converting enzyme inhibitors. Absolute risk difference was -0.10 [-0.19, -0.02], with a number needed to treat of 10 [6-50] patients to avoid one event. CRP -0.69 [-1.69, 0.31] was not significantly reduced by RIPC.ConclusionsRIPC reduced the incidence of PMI following PCI, especially when performed in the lower limb and for patients with multivessel disease and complex lesions.

26 keywords...

hide…